Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL. 1, 2011, Pages

  Pagano, Livio ^a   Akova, Murat ^b   Dimopoulos, George ^c   Herbrecht, Raoul ^d   Drgona, Lubos ^e   Blijlevens, Nicole ^f  

^a CATHOLIC UNIVERSITY   (Italy)

^b HACETTEPE UNIVERSITY   (Turkey)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d HÔPITAL DE HAUTEPIERRE   (France)

^e CANCER RESEARCH INSTITUTE   (Slovakia)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Environment; Immune system; Moulds; Prognostic factors; Risk factors

Indexed keywords

ANTINEOPLASTIC AGENT; DEFEROXAMINE; ETANERCEPT; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; ASPERGILLUS FUMIGATUS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANDIDA; CANDIDIASIS; CARDIAC GRAFT REJECTION; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; ENVIRONMENTAL EXPOSURE; GENETIC RISK; GENETIC VARIABILITY; HEART TRANSPLANTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; IMMUNOCOMPROMISED PATIENT; INVASIVE ASPERGILLOSIS; IRON OVERLOAD; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHATIC LEUKEMIA; LYMPHOCYTOPENIA; LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; MYELOPROLIFERATIVE DISORDER; NEUTROPENIA; NONHUMAN; PROGNOSIS; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; ZYGOMYCETES; ZYGOMYCOSIS;

FUNGI; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MYCOSES; NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; TRANSPLANTATION;

EID: 78650546347     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq437     Document Type: Article

References (71)

1. Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-9.
2. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM 2004 study. Haematologica 2006; 91: 1068-75.
3. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study. Clin Infect Dis 2007; 45: 1161-70.
4. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803.
5. Cornet M, Fleury L, Maslo C et al. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002; 51: 288-96.
6. Singh N, Husain S, AST Infectious Diseases Community of Practice. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S180-91.
7. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69.
8. Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
9. Lortholary O, Ascioglu S, Moreau P et al. Invasive aspergillosis as an opportunistic infection in non-allografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myelome. Clin Infect Dis 2000; 30: 41-6.
10. Mlonakis E, Barlam TF, Flanigan T et al. Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. Chest 1998; 114: 251-62.
11. Kim HJ, Park YJ, Kim WU et al. Invasive fungal infections in patients with systemic lupus erythematosus: experience from affiliated hospitals of Catholic University of Korea. Lupus 2009; 18: 661-6.
12. Mezger M, Einsele H, Loeffler J. Genetic susceptibility to infections with Aspergillus fumigatus. Crit Rev Microbiol 2010; 36: 168-77.
13. Seo KW, Kim DH, Sohn SK et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 1089-95.
14. Sainz J, Perz E, Hassan L et al. Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. Hum Immunol 2007; 68: 41-50.
15. Bochud PY, Chien JW, Marr KA et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359: 1766-77.
16. Kesh S, Mensah NY, Peterlongo P et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci 2005; 1062: 95-103.
17. Zaas A, Liao G, Chien J et al. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet 2008; 4: e1000101.
18. Lambourne J, Agranoff D, Herbrecht R et al. Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2009; 49: 1486-91.
19. Brenier-Pinchart MP, Lebeau B, Quesada JL et al. Influence of internal and outdoor factors on filamentous fungal flora in hematology wards. Am J Infect Control 2009; 37: 631-7.
20. Panackal AA, Li H, Kontoyiannis DP et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 2010; 50: 1588-97.
21. Lass-Flörl C, Eschertzhuber S, Auberger J et al. Airborne fungus-exposure prior hospitalization as risk factor for mould infections in immunocompromised patients. In: Abstracts of Nineteenth European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Helsinki, Finland, 2009. Abstract O243, p. 118. European Society of Clinical Microbiology and Infectious Diseases.
22. Terr AI. Sick building syndrome: is mould the cause? Med Mycol 2009; 47 Suppl 1: S217-22.
23. Weber DJ, Peppercorn A, Miller MB et al. Preventing healthcare-associated Aspergillus infections: review of recent CDC/HICPAC recommendations. Med Mycol 2009; 47 Suppl 1: S199-209.
24. Bénet T, Nicolle MC, Thiebaut A et al. Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure. Clin Infect Dis 2007; 45: 682-6.
25. Abdul Salam ZH, Karlin RB, Ling ML et al. The impact of portable high-efficiency particulate air filters on the incidence of invasive aspergillosis in a large acute tertiary-care hospital. Am J Infect Control 2010; 38: e1-7.
26. Lass-Flörl C, Rath P, Niederwieser D et al. Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J Hosp Infect 2000; 46: 31-5.
27. Anaissie EJ, Stratton SL, Dignani MC et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood 2003; 101: 2542-6.
28. Cunha C, Di Ianni M, Bozza S et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient-and donor-dependent mechanisms of antifungal immunity. Blood 2010; doi:10.1182/blood-2010-04-279307.
29. Bodey GP. Infectious complications of acute leukemia. Med Times 1966; 94: 1076-85.
30. Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol 2009; 27: 3849-54.
31. Fianchi L, Valentini CG, Posteraro B et al. Functional in vitro evaluation of bactericidal and fungicidal activity of neutrophils from patients suffering from myelodysplasia. Haematologica 2009; 94(s4): 195-6.
32. Garcia-Vidal C, Upton A, Kirby KA et al. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-50.
33. Palmer LB, Greenberg HE, Schiff M. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax 1991; 46: 15-20.
34. Ng TTC, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994; 140: 2475-9.
35. Thursky K, Byrnes G, Grigg A et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 115-21.
36. Laros-van Gorkom BA, Huisman CA, Wijermans PW et al. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. Neth J Med 2007; 65: 333-8.
37. Gil L, Kozlowska-Skrzypczak M, Mol A et al. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant 2009; 43: 121-6.
38. Tsiodras S, Samonis G, Boumpas DT et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008; 83: 181-94.
39. Kontoyiannis DP, Chamilos G, Lewis RE et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007; 110: 1303-6.
40. Altes A, Remacha AF, Sarda P et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 2004; 34: 505-9.
41. de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 1994; 47: 1843-50.
42. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 2008; 21: 620-5.
43. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis 2010; 50: 1091-100.
44. Parody R, Martino R, Rovira M et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 2006; 12: 734-48.
45. Miyakoshi S, Kusumi E, Matsumura T et al. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. Biol Blood Marrow Transplant 2007; 13: 771-7.
46. Mikulska M, Raiola AM, Bruno B et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009; 44: 361-70.
47. Martino R, Piñana JL, Parody R et al. Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant 2009; 44: 749-56.
48. van Burik JA, Carter SL, Freifeld AG et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 1487-98.
49. Fukuda T, Boeckh M, Guthrie KA et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494-503.
50. Gavaldà J, Len O, San Juan R et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41: 52-9.
51. Pagano L, Valentini CG, Caira M et al. Zygomycosis: current approaches to management of patients with haematological malignancies. Br J Haematol 2009; 146: 597-606.
52. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycoses in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-60.
53. Trifilio SM, Bennett CL, Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-9.
54. Wingard WR, Carter SL, Walsh TJ et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood 2007; 110: 163.
55. Lionakis MS, Kontoyiannis DP. Fusarium infections in critically ill patients. Semin Respir Crit Care Med 2004; 25: 159-69.
56. Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect 2010; 60: 331-7.
57. Husain S, Munoz P, Forrest G et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40: 89-99.
58. Meersseman W, Lagrou K, Maertens J et al. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45: 205-16.
59. Guinea J, Torres-Narbona M, GijónPet al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 2010; 16: 870-7.
60. Antinori S, Nebuloni M, Magni C et al. Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: a retrospective study of 1,630 autopsies performed between 1984 and 2002. Am J Clin Pathol 2009; 132: 221-7.
61. Pagano L, Caira M, Candoni A et al. Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. Haematologica 2010; 95: 644-50.
62. Parody R, Martino R, Sánchez F et al. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Am J Hematol 2009; 84: 571-8.
63. Nivoix Y, Velten M, Letscher-Bru V et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-84.
64. Cordonnier C, Ribaud P, Herbrecht R et al. Prognostic factors for death due to invasive aspergillosis after hemopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42: 955-63.
65. Upton A, Kirby KA, Carpenter P et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-40.
66. Baddley JW, Andes DR, Marr KA et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50: 1559-67.
67. Howard SJ, Cerar D, Anderson MJ et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-76.
68. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-9.
69. Cornillet A, Camus C, Nimubona S et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43: 577-84.
70. Koo S, Bryar JM, Baden LR et al. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010; 48: 1255-60.
71. Rodriguez-Tudela JL, Berenguer J, Guarro J et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 2009; 47: 359-70.